BEGEV挽救方案治疗复发难治性经典型霍奇金淋巴瘤的5年结果
该研究报道BEGEV方案(苯达莫司汀、吉西他滨、长春瑞滨)序贯自体干细胞移植(ASCT)治疗复发/难治性经典型霍奇金淋巴瘤(cHL)的5年随访结果。全组59例中位随访5年,无进展生存(PFS)率59%、总生存(OS)率78%;49例缓解患者中43例接受ASCT,移植患者5年PFS率77%、OS率91%,且未观察到继发性白血病或骨髓增生异常。
要点
- BEGEV方案诱导后全组5年PFS率59%、OS率78%。
- 移植患者5年PFS率77%、OS率91%,复发与难治患者无显著差异。
- 未观察到继发性白血病或骨髓增生异常。
核心结论
- BEGEV方案序贯ASCT在复发/难治性cHL中显示出长期疗效和良好安全性。
研究设计与样本
- 报道BEGEV方案序贯ASCT治疗复发/难治性cHL的5年随访结果,全组共59例。
主要发现
- 全组中位随访5年,PFS率为59%,OS率为78%。
- 49例缓解患者中43例接受ASCT,其中33例持续完全缓解(意向性分析56%,移植患者77%),7例疾病复发,3例非复发死亡。
- 移植患者5年PFS率为77%,OS率为91%,复发与难治患者间无显著差异。
- 未观察到继发性白血病或骨髓增生异常。
临床怎么用
- BEGEV方案可作为复发/难治性cHL患者ASCT前的诱导化疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The complete remission (CR) rate achieved with induction chemotherapy prior to autologous stem cell transplantation (ASCT) represents the strongest prognostic factor in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). By inducing a CR rate of 75%, the bendamustine, gemcitabine, vinorelbine (BEGEV) regimen represents an optimal chemotherapy regimen prior to ASCT. Presented here are the 5-year results of BEGEV followed by ASCT in R/R cHL. With a median follow-up of 5 years, progression-free survival (PFS) and overall survival (OS) for the whole series (n = 59) were 59% and 78%, respectively. ASCT was performed in 43 of 49 responding patients (73% by intention to treat [ITT]; 88% by response to BEGEV) and resulted in 33 with continuous CR (56% by ITT; 77% of transplanted patients), 7 with disease relapse, and 3 with nonrelapse mortality. For patients who received transplants, the 5-year PFS and OS were 77% and 91%, respectively, with no significant difference between relapsed and refractory patients. No patient experienced secondary leukemia or myelodysplasia. In summary, the long-term efficacy data, the benefits for both relapsed and refractory patients, and the excellent safety profile provide a strong rationale for further development of the BEGEV regimen. This trial was registered at EudraCT as #2010-022169-91 and at www.clinicaltrials.gov as #NCT01884441.
引用
- Santoro A, Mazza R, Pulsoni A, et al. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2020. PMID: 31935284. doi:10.1182/bloodadvances.2019000984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。